

# Stephen E M Langley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8035830/publications.pdf>

Version: 2024-02-01

23  
papers

411  
citations

933264

10  
h-index

839398

18  
g-index

23  
all docs

23  
docs citations

23  
times ranked

572  
citing authors

#	ARTICLE	IF	CITATIONS
1	Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU International, 2012, 109, 7-16.	1.3	104
2	The role of transperineal template prostate biopsies in restaging men with prostate cancer managed by active surveillance. BJU International, 2012, 109, 1170-1176.	1.3	67
3	Importance of HOX genes in normal prostate gland formation, prostate cancer development and its early detection. BJU International, 2014, 113, 535-540.	1.3	51
4	Long-term oncological outcomes and toxicity in 597 men aged 60 years at time of low-dose-rate brachytherapy for localised prostate cancer. BJU International, 2018, 121, 38-45.	1.3	27
5	Long-term toxicity and quality of life up to 10 years after low-dose rate brachytherapy for prostate cancer. BJU International, 2012, 109, 994-1000.	1.3	26
6	Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database. BJU International, 2007, 99, 1398-1403.	1.3	19
7	Novel prostate brachytherapy technique: Improved dosimetric and clinical outcome. Radiotherapy and Oncology, 2008, 88, 121-126.	0.3	18
8	4D Brachytherapy, a novel real-time prostate brachytherapy technique using stranded and loose seeds. BJU International, 2012, 109, 1-6.	1.3	18
9	Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy. BJU International, 2006, 98, 1210-1215.	1.3	16
10	Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible. BJU International, 2015, 115, 580-586.	1.3	14
11	Are prostatic biopsies necessary in men aged >80 years?. BJU International, 2007, 99, 335-338.	1.3	11
12	Fertility after prostate brachytherapy. BJU International, 2005, 96, 915-915.	1.3	10
13	Does Prostate HistoScanning accurately identify prostate cancer, measure tumour volume and assess pathological stage prior to radical prostatectomy?. Journal of Clinical Urology, 2013, 6, 395-402.	0.1	8
14	Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse. BJU International, 2018, 122, 610-617.	1.3	8
15	Low-Dose-Rate Prostate Brachytherapy (LDRPB) adopts postsurgical PSA value for definition of cure. BJU International, 2021, 2, 9-10.	0.7	5
16	Investigating the associations of mucosal P2Y6 receptor expression and urinary ATP and ADP concentrations, with symptoms of overactive bladder. Neurourology and Urodynamics, 2020, 39, 926-934.	0.8	4
17	Robot-assisted salvage seminal vesicle excision for isolated recurrence after low-dose-rate prostate brachytherapy. BJU International, 2022, 129, 731-736.	1.3	3
18	Long-term survival after low-dose-rate brachytherapy for prostate cancer: the Royal Surrey experience. BJU International, 2022, 129, 723-730.	1.3	2

#	ARTICLE	IF	CITATIONS
19	Brachytherapy for Prostate Cancer. , 2018, , 87-98.		0
20	Low-dose-rate brachytherapy for prostate cancer stands the test of time – the Swiss experience. BJU International, 2020, 125, 750-751.	1.3	0
21	Brachytherapy for Prostate Cancer. , 2015, , 743-772.		0
22	Risk-assessed exercise and diet in prostate cancer survivors: Consequences of cancer treatment on cardiopulmonary fitness and cardiovascular risk.. Journal of Clinical Oncology, 2017, 35, 142-142.	0.8	0
23	Prostate cancer treatment. Permanent low-dose rate prostate brachytherapy. Annals of the Royal College of Surgeons of England, 2006, 88, 442-4.	0.3	0